Clinical Trials & Research

A nationwide case-control study conducted in France has assessed the efficacy of mRNA-based coronavirus disease 2019 (COVID-19) vaccines against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, including B.1.1.7, B.1.351, and P1. In real-life pandemic situations, the two-dose regimen of mRNA vaccines has shown equivalent protective efficacy against the original virus and

CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ – Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final results from the Phase 2 ANT-005 study with its novel investigational anticoagulant abelacimab. Published today in the New England Journal of Medicine,1 and simultaneously presented as a late breaker at the International Society of Thrombosis and

The ongoing coronavirus disease pandemic 2019 (COVID-19), which is caused by a novel betacoronavirus – namely the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) –  has led to immense disruptions to public health and economic wellbeing worldwide. Scientists have developed COVID-19 vaccines at a record speed, and several of these have received emergency use approval

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 17, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) today announced new results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV. The findings demonstrate that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high

Wildfire smoke may greatly increase susceptibility to SARS-CoV-2, the virus that causes COVID-19, according to new research from the Center for Genomic Medicine at the Desert Research Institute (DRI), Washoe County Health District (WCHD), and Renown Health (Renown) in Reno, Nev. In a study published earlier this week in the Journal of Exposure Science and

KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE) July 12, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. The data were

Researchers have found that individuals with learning disabilities are more likely to suffer from severe cases of COVID-19 infection, with higher rates of hospitalization and mortality, which is exacerbated for individuals with profound disabilities such as Down’s syndrome and cerebral palsy. SARS-CoV-2 Virus. Image Credit: Corona Borealis Studio/Shutterstock.com Further evidence indicating symptom severity of COVID-19

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) over time NEW BRUNSWICK, N.J., July 14, 2021 – Interim results from a Phase 1/2a sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by

Researchers from Kumamoto University, Japan have found that a component derived from turmeric essential oil, aromatic turmerone (ar-turmerone), and its derivatives act directly on dopaminergic nerves to create a neuroprotective effect on tissue cultures of a Parkinson’s disease model. This appears to be due to enhanced cellular antioxidant potency from the activation of Nrf2. The

28 June 2021 — The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.1 The trial assessed the safety of nirsevimab in infants with chronic lung disease (CLD), congenital heart disease (CHD) and/or prematurity.

Is it possible to completely get rid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants? New research led by Neta S. Zuckerman of Sheba Medical Center in Israel suggests it’s possible. Their report details the upsurge of a B.1.362 variant harboring the L452R mutation that eventually disappeared due to vaccination efforts and the presence

28 June 2021 — A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. The results, published by the University of Oxford on the pre-print server of The Lancet, demonstrated that antibody levels remain elevated from

The following quote is attributed to Frank Yiannas, Deputy Commissioner for Food Policy and Response In order to fulfill our public health mission and enhance the safety of imported foods in a global world, we must embrace new approaches that take into account the entire supply chain and its complexity. This draft guidance addresses the

NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight

Advancing options for persons living with chronic back pain, UC San Diego Health has completed the first surgery in the nation to implant a device that uses neurostimulation in the form of electrical pulses to key nerves and muscles responsible for stabilizing the lower back. We are seeing incredible innovation in using neuromodulation to target

GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ – Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of its COVID-19 vaccine candidate conducted in the United Kingdom in the New England Journal of Medicine (NEJM). The final analysis confirmed an overall

A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the medRxiv* preprint server. Background Hypercoagulation and

South San Francisco, CA — June 24, 2021 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years

Migraine is one of the largest causes of disability in the world. Existing treatments are often not enough to offer full relief for patients. A new study published in The BMJ demonstrates an additional option patients can use in their effort to experience fewer migraines and headaches – a change in diet. “Our ancestors ate

INDIANAPOLIS, June 25, 2021 /PRNewswire/ — Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company’s (NYSE: LLY) SURPASS-2 clinical trial, which were simultaneously published today in The New England Journal of Medicine (NEJM)1 and presented in a late breaking poster presentation during the American

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is strange in the breadth of severity in its clinical manifestations, ranging from asymptomatic to fatal infection. The ability to predict severe disease and thus intervene early is important, and has spurred the search for markers of this shift. An

INDIANAPOLIS, June 26, 2021 /PRNewswire/ – Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company’s (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo. Detailed SURPASS-1 results were presented

A large cohort study drawn from the national IVF registry of France, which included almost 70,000 pregnancies delivered after 22 weeks gestation between 2013 and 2018, has found a higher risk of pre-eclampsia and hypertension in pregnancies derived from frozen-thawed embryos. This risk was found significantly greater in those treatments in which the uterus was

INDIANAPOLIS, June 24, 2021 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). The Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates

A new discovery in rats shows that the brain responds differently in immersive virtual reality environments versus the real world. The finding could help scientists understand how the brain brings together sensory information from different sources to create a cohesive picture of the world around us. It could also pave the way for “virtual reality

15 June 2021 — AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442

The U.S. continues to see Covid-19 vaccinations gradually increasing nationwide, with nearly 66% of all adults now having at least one vaccine dose according to CDC’s COVID Data Tracker, yet disparities have been noted in vaccination rates across races and geographic areas. A new dashboard shows differences in vaccination rates by race across Georgia’s counties.

EAST HANOVER, N.J., June 4, 2021 – Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001).1 The study evaluated tislelizumab in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who